Sino Biopharmaceutical Azioni (OTC: SBHMY)

Ultime notizie per Sino Biopharmaceutical (OTC:SBHMY) Azioni

Sino Biopharmaceutical

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

SINO BIOPHARM UNSP/ADR by Sino Biopharmaceutical Ltd.

Sino Biopharmaceutical Ltd

<a href="https://www.benzinga.com/personal-finance/24/09/40985018/mark-cubans-black-amex-card-was-declined-trying-to-buy-a-140-000-bottle-of-champagne-after-his-n">Billionaire Mark Cuban</a> shared some candid insights about parenting on The Steam Room Podcast in November, hosted by Charles Barkley and Ernie Johnson. When Barkley asked Cuban how he avoids spoiling his kids despite his massive fortune, Cuban responded with a phrase that's as sharp as it is simple: "It's my money, not yours."
It's a sentiment echoed by other wealthy parents, like Shaquille O'Neal, who famously said, <a href="https://www.benzinga.com/personal-finance/24/09/40943843/we-aint-rich-im-rich-nba-legend-shaq-says-his-daughters-and-sons-dont-get-equal-treatment-my-boy">"We ain't rich, I'm rich"</a> and Bill and Melinda Gates, who emphasized a "<a href="https://www.benzinga.com/personal-finance/24/07/40015377/bill-gates-children-will-only-inherit-10-million-0-0077-of-his-net-worth-leaving-kids-massive-am">middle-class upbringing</a>" for their kids. But Cuban's take feels especially personal when you hear how he talks about his three kids.
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
"You know what it's like," Cuban told Barkley. "Your kids – no, you think they're going to be like you and your wife, but they end up being their own little humans." He described his children&#8217;s unique personalities: "One takes advantage, the other two don't. The middle one rebels against it … and my son, the youngest, takes advantage a little bit of tech because he knows I'll give in."
Even so, Cuban insists on keeping things grounded at home. "They still have to wash dishes, they still have to clean up after themselves – most of the time," he said. While he acknowledges that it's not easy – "They're getting on a private plane most of the time and it's not like we can hide it from them" – he's determined to avoid the trap of throwing material things at them as a solution. "You're mad at me? Let me buy you something. You're sad? Let me buy you something. That's just not how it works."
See Also: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
The conversation feels refreshingly human, especially coming from someone whose life seems anything but ordinary. It's one thing to talk about discipline when your kids are flying coach, but Cuban's perspective shows that the challenges of raising "grateful and great human beings," as Barkley put it, exist at every level.
It's a mindset shared by other high-profile figures like Shaq, who requires his kids to earn two degrees before they can access his wealth. The underlying principle? Wealth shouldn't define your kids but challenge them to find their paths.
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Back in 2014, Mark Cuban <a href="https://www.benzinga.com/personal-finance/24/10/41433888/dave-ramsey-tells-mark-cuban-regardless-of-socio-economic-status-you-have-to-teach-kids-to-work">appeared on The Dave Ramsey Show</a> and opened up about teaching kids the value of hard work. He also shared some of his biggest concerns as a parent. "Their health is number one, my number one fear and then just not being jerks is number two," Cuban said.
Mark Cuban's honesty about his parenting style – <a href="https://www.benzinga.com/money/are-you-rich">balancing privilege with responsibility – </a>might not be a one-size-fits-all solution, but it's clear he's trying to do more than just raise rich kids. He's raising adults.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
</ul>

Personal Finance

Billionaire Mark Cuban Says He Doesn't Spoil His Kids And Tells Them 'It's My Money, Not Yours'

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 10.11% on an annualized basis producing an average annual return of 18.44%. Currently, Illumina has a market capitalization of $21.57 billion. 
Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $2,976.69 today based on a price of $135.99 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735056016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

ILMN

Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years

In the current session, the stock is trading at $113.82, after a 0.65% spike. Over the past month, Arista Networks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) stock increased by 11.50%, and in the past year, by 91.51%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1735056007_0.png" alt="Past Year Chart" />

<h3>Comparing Arista Networks P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Arista Networks has a better P/E ratio of 54.3 than the aggregate P/E ratio of 49.32 of the Communications Equipment industry. Ideally, one might believe that Arista Networks Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1735056007_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

ANET

P/E Ratio Insights for Arista Networks

AVGR

Avinger Shares Halted On Circuit Breaker To The Upside, Stock Now Up 164.6%

SoundHound AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares are trading lower on Tuesday, pulling back from recent strength. The rally accelerated in November when the company reported strong earnings. Here&#8217;s what you <a href="https://www.benzinga.com/tech/24/12/42628373/exclusive-soundhound-ai-ceo-on-882-growth-were-just-getting-started">need to know</a>.
What To Know: SoundHound shares are up more than 875% since the start of the year, buoyed by the company&#8217;s positioning in the AI space. The stock has nearly tripled since mid-November when the company reported better-than-expected quarterly results, marking its &#8220;largest quarter on record.&#8221;
SoundHound reported a third-quarter loss of 6 cents per share, beating estimates of a loss of 7 cents per share. The company reported revenue of $25.1 million, beating estimates of $23.02 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. SoundHound said demand was driven by &#8220;incredible market enthusiasm&#8221; for conversational AI tools.
SoundHound shares continued to move higher following earnings after Nvidia reported investments in multiple companies, including SoundHound, in a 13-F filing with the SEC. Nvidia&#8217;s 13F <a href="https://www.sec.gov/Archives/edgar/data/1045810/000104581024000305/xslForm13F_X02/information_table.xml">latest filing</a> showed that it increased its stake in SoundHound by about 18% in the third quarter.
Analysts lifted price targets as the stock has continued to trend higher. Last Week, Wedbush analyst Dan Ives maintained SoundHound with an <a href="https://www.benzinga.com/analyst-stock-ratings">Outperform</a> rating and raised its price target from $10 to $22. On Monday, HC Wainwright &amp; Co. analyst Scott Buck maintained a Buy rating on the stock and raised its price target from $8 to $26.
See Also: <a href="https://www.benzinga.com/news/large-cap/24/12/42668623/american-airlines-resolves-nationwide-flight-grounding-on-christmas-eve-shares-rebound-after-brief-selloff">American Airlines Lifts Christmas Eve Grounding, Shares Bounce Back</a>
It&#8217;s worth noting that SoundHound has high short interest with 24.4% of the float currently sold short, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>. SoundHound has also been showing up on Benzinga&#8217;s <a href="https://www.benzinga.com/trading-ideas/24/12/42628286/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-including-qubt-qbts">Stock Whisper Index</a> in recent weeks. 
In an exclusive interview on Friday, SoundHound CEO Keyvan Mohajer told Benzinga that AI has moved from the exploratory phase to the mandatory phase for budgets.
&#8220;In that context, SoundHound is in a prime position. Our ability to combine proprietary voice AI technology with sophisticated large language models has allowed us to deliver immense value,&#8221; Mohajer said. 
The SoundHound CEO told Benzinga that the company is powering hundreds of global enterprise brands, thousands of restaurant and retail locations and millions of vehicles and devices.
&#8220;And we&#8217;re just getting started,&#8221; Mohajer said.
SOUN Price Action: <a href="http://benzinga.com/quote/soun">SoundHound shares</a> were flat at 0.34% at $20.45 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42628286/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-including-qubt-qbts">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet, Including QUBT, QBTS</a></li>
</ul>
Photo: Shutterstock.

Movers

SOUN

What's Going On With SoundHound AI Stock?

Avinger Shares Resume Trade

HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) announced on Tuesday its acquisition and deployment of advanced Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) H100 and H200 GPU clusters <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/42665811/hive-expands-nvidia-chip-suite-to-power-ai-boom-with-30-million-h100-and-h200-gpu-clusters-to-be-de" rel="noreferrer noopener">in Quebec, Canada</a>.
This strategic $30 million investment aims to strengthen HIVE&#8217;s position in artificial intelligence (AI) and high-performance computing (HPC) and enhance its role in the digital transformation landscape.
The new GPU clusters are part of HIVE&#8217;s broader strategy to drive growth in AI and HPC markets.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/12/42613368/broadcom-expects-decade-long-ai-chip-boom-as-big-tech-invest-billions" rel="noreferrer noopener">Broadcom Expects Decade-Long AI Chip Boom as Big Tech Invest Billions</a>
HIVE expects the latest technology to significantly boost its annualized run-rate revenue and margin growth in the coming quarters.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24062648/newplot-14.png" alt="" class="wp-image-705809" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24062648/newplot-14.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24062648/newplot-14-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
The Nvidia H100 cluster, consisting of 248 GPUs across 32 nodes, is fully configured and set to be operational by the end of 2024. Once deployed, this cluster will likely generate ~$15 million in annualized run-rate revenue.
The Nvidia H200 cluster, featuring 508 GPUs in 64 nodes, is scheduled to arrive in early January 2025 and be deployed in the first quarter of 2025.
HIVE projects over $20 million in annualized run-rate revenue from the H200 cluster by the second quarter of 2025.
Aligned with its commitment to sustainability, HIVE powers its operations in Quebec entirely with renewable energy.
In October, Cantor Fitzgerald&#8217;s Brett Knoblauch <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41603920/hive-pushes-hash-rate-higher-sharpens-focus-on-ai" rel="noreferrer noopener">highlighted HIVE&#8217;s measured</a> approach to growth, contrasting it with peers focusing on aggressive expansion.
He noted that the company prioritizes maximizing returns from fleet investments over rapid scaling, which has led to underperformance relative to competitors.
The analyst expects HIVE to double its hash rate in the coming year while maintaining its top-tier mining efficiency. He also pointed out HIVE&#8217;s advancements in AI and high-performance computing (HPC), emphasizing the potential of its GPU cloud platform, HIVE Cloud.
HIVE&nbsp;stock plunged over 32% year-to-date.
Price Actions:&nbsp;HIVE stock is up 2.69% at $3.05 at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42621868/nvidia-secures-eu-approval-for-runai-deal-us-probes-china-export-breach" target="_blank" rel="noreferrer noopener">Nvidia Secures EU Approval For Run:ai Deal, US Probes China Export Breach</a></li>
</ul>
Photo by rafapress via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

HIVE

NVDA

HIVE Digital Boosts AI Ambitions With $30 Million Nvidia GPU Deployment

Avinger Shares Halted On Circuit Breaker To The Upside, Stock Now Up 128.8%

Strategic location offers unique opportunity to ensure reliability for the New England region and advance Massachusetts&#39; clean energy transition by interconnecting multiple renewable energy sources
With a focus on helping to enable Massachusetts&#39; unprecedented clean energy transition while ensuring safe, reliable service for customers across New England, Eversource has acquired a 26-acre portion of the Mystic property from Constellation Energy. Eversource has not developed specific plans for the site at this time, but its strategic location, historic use, and existing infrastructure uniquely position it as a potential multi-use energy interconnection hub for large-scale renewable energy sources &ndash; including onshore or offshore wind, hydro, battery storage and nuclear among others &ndash; with the capacity to support electrification and meet the reliability needs for major energy users in the region. Over the coming year, Eversource will collaborate closely with Massachusetts and Everett officials and other stakeholders to develop a plan for the property, which is adjacent to the site of the proposed soccer stadium in Everett, to improve electric reliability in New England while also helping to advance Massachusetts&#39; electrification and decarbonization goals.

Eversource Acquires Mystic Property From Constellation Energy; No Financial Terms Disclosed

IAG, the parent of British Airways,&nbsp;is weighing options with multiple providers, including&nbsp;Amazon.com Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Project Kuiper and Elon Musk&#8217;s Starlink to equip its fleet with Wi-Fi service, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-12-24/spacex-amazon-in-talks-with-british-airways-owner-on-wi-fi-deal?sref=TBDibEcD" rel="noreferrer noopener">cites</a> from an interview with IAG&#8217;s head of innovation,&nbsp;Annalisa Gigante.
According to the report, Gigante acknowledged working with Starlink and Amazon&#8217;s Kuiper towards something likely for 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42536024/taiwan-eyes-amazons-kuiper-as-starlink-faces-hurdles" rel="noreferrer noopener">Amazon&#8217;s Project Kuiper In Talks With Taiwan For Satellite Partnership</a>
According to the Bloomberg report, while U.S. airlines can easily switch to Starlink because the&nbsp;Federal Aviation Administration has already authenticated it, European carriers have to undergo a certification process. British Airways would need a separate certification from Iberia, she said.
Amazon plans to launch the first operational Kuiper satellites&nbsp;by 2025.
The talks reflect airlines forging deals with Starlink and rivals for faster, affordable, unlimited in-flight Wi-Fi. Starlink boasts of ~4 million customers.
In March, Icelandair selected ViaSat Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) <a target="_blank" href="https://www.benzinga.com/markets/equities/24/03/37485751/viasat-secures-icelandair-deal-for-inflight-wi-fi-on-new-airbus-fleet" rel="noreferrer noopener">for Wi-Fi on</a> the new Airbus fleet to ensure an online experience with streaming entertainment.
In May, Qatar Airways collaborated with&nbsp;Starlink&nbsp;to <a target="_blank" href="https://www.benzinga.com/news/24/05/39081646/elon-musks-starlink-joins-hands-with-qatar-airways-for-menas-first-complimentary-wi-fi-service-on-se" rel="noreferrer noopener">offer complimentary Wi-Fi</a> on three of its Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) 777-300 aircraft.
In September, United Airlines Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) announced <a target="_blank" href="https://www.benzinga.com/news/24/09/40853157/united-airlines-inks-deal-with-elon-musks-spacex-to-provide-free-inflight-wi-fi-via-starlink" rel="noreferrer noopener">plans to offer</a> free inflight Wi-Fi to its passengers, leveraging Starlink service.
Also in September, Hawaiian Airlines Airbus-operated flights announced <a target="_blank" href="https://www.benzinga.com/news/24/09/41023552/hawaiin-airlines-airbus-planes-take-flight-with-starlink-internet-service-at-no-additional-cost-to-c" rel="noreferrer noopener">the availability of</a> Starlink satellite internet service.
Price Action: AMZN stock is up 1.73% at $228.91 at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42668021/lockheed-martin-secures-337-billion-f-35-contract-and-more" target="_blank" rel="noreferrer noopener">Lockheed Martin Secures $3.37 Billion F-35 Contract And More</a></li>
</ul>
Photo via Shutterstock

Tech

Media

AMZN

VSAT

British Airways Parent Targets Advanced Wi-Fi Options with Musk's Starlink and Amazon's Kuiper

While computer memory specialist Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) fundamentally benefits from the surge in artificial intelligence — largely because of its high-performance memory and storage solutions — MU stock <a href="https://www.benzinga.com/topic/micron">suffered a rude awakening recently. </a>
Last week, shares tumbled almost 15% following the company's rather <a href="https://www.benzinga.com/news/earnings/24/12/42564387/micron-q1-earnings-revenue-miss-eps-beat-soft-guidance-sinks-shares-as-consumer-markets-turn-weaker-in-near-term">disappointing earnings report</a>. Still, astute risk-takers may find upside opportunity in the carnage.
After the market closed last Wednesday, Micron released its results for the first quarter of fiscal 2025. Adjusted earnings per share landed at $1.79, beating the consensus view of $1.76. However, the market didn't take too kindly to the tech giant generating sales of $8.71 billion, thus missing the expected tally of $8.72 billion.
However, it was likely guidance that sent investors rushing for the exits. Management anticipates that in the current quarter, revenue might land at only $7.9 billion, give or take $200 million. Either way, that's short of analysts' estimate of $9 billion. Adding to the woes, Micron expects Q2 adjusted EPS to reach $1.43, plus or minus 10 cents. This figure pales in comparison to the prior estimate of $1.92.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="598" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24061822/MU-stock-12242024-1024x598.jpg" alt="" class="wp-image-705803" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24061822/MU-stock-12242024-1024x598.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24061822/MU-stock-12242024-300x175.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24061822/MU-stock-12242024-768x449.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24061822/MU-stock-12242024.jpg 1027w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
With this trade, MU stock has now fallen back into the clutches of a horizontal consolidation pattern that began in late July of this year. Because of the rarity of one-week drops exceeding 10%, investors have reason to be cautious. Nevertheless, data-driven traders may view Micron stock as a compelling comeback opportunity.
<h2 class="wp-block-heading">Leveraging the Power of Probabilistic Analysis</h2>
In physics, aircraft engineers <a href="https://calaero.edu/aeronautics/principles-of-flight/newtons-third-law-in-aviation/">primarily rely on Newtonian mechanics</a> to design stable airplanes. Essentially, flight dynamics of objects near the earth's surface can be reliably predicted with classical physics. However, satellites require an <a href="https://chandra.harvard.edu/blog/node/773">Einsteinian model</a> or general and special relativity, in part to account for weaker gravitational fields and other unique dynamics in space.
The financial markets work in a similar manner. Many, if not most, technical analysis indicators are derived through linear, deterministic (i.e., Newtonian) frameworks. They monitor the frequencies of a given event over a defined period of time.
For example, under a frequentist approach, it's straightforward to calculate the probability that, on any given Monday, the market will deliver a positive return by Friday's close. In this case, the trader divides the number of positive weeks in a given dataset by the total number of weeks in that dataset. The success ratio for MU stock over the past five years is 49.4%.
However, what happened last week is a rare event. Over the same five-year period, there were only nine weeks (not including last week) where MU stock lost 10% or more. Of this figure, six of the following weeks ended in positive territory (or a success ratio of 66.67%), with an average return of 6.22%. These figures can be attained via a probabilistic analysis called Bayesian inference.
At its core, the character of speculation in MU stock changes dramatically following a deep loss of weekly value. Much like Einstein's theory of relativity accounts for large objects' disruption of the space-time continuum, Bayesian inferences help capture the sentiment shift of extreme greed that occurs following a period of extreme fear.
<h2 class="wp-block-heading">Bull Call Spreads of MU Stock to Target</h2>
To put it simply, determining the success ratio of any given week is basically a coin toss. However, this week is special because it follows a week where MU stock lost almost 15% of value. Such events are quite rare and when they occur, they tend to shift the fear-greed continuum decisively in favor of the bulls. Of course, that doesn't guarantee success. However, a trader would be betting with the wind at their back.
Understanding this framework, there are two approaches to consider, both involving <a href="https://www.benzinga.com/money/bull-spread">bull call spreads</a> that expire this coming Friday (Dec. 27). One idea is to buy the 88/90 call spread or buying the $88 call and simultaneously selling the $90 call. Here, the credit received from the short call helps partially offset the debit paid for the long call.
The net debit paid comes out to $149 (as of Monday's close), which is the most that can be lost in the trade. Further, the payout is the difference between the strike prices minus the net debit paid, which is $51 or 34.23%.
However, as stated earlier, the Bayesian calculation revealed that when a positive week follows a 10% or greater loss in the prior week, the average return is 6.22%. Applying this figure to Monday's close reveals an upside target price of $95.30. By logical deduction, an aggressive bull call spread could feature a short call strike of $95.
For instance, an intrepid speculator could buy an 88/95 call spread. That puts $252 at risk for the chance to earn $448 should MU stock hit or exceed $95 by Friday, or a payout of 177.78%. Again, it's an aggressive bet and the market makers — who are likely using deterministic math — have calculated very low odds of success, hence the big payout.
In contrast, probabilistic math based on special circumstances (such as the current week) yields a completely different framework. This is the inside edge that investors should consider when assessing MU stock amid the earnings aftermath.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42667044/teslas-valuation-could-exceed-all-transport-companies-but-spacex-ceo-elon-musk">Tesla&#8217;s Valuation Could Exceed All Transport Companies But SpaceX, Says CEO Elon Musk, But Notes It Will Take A &#8216;Lot Of Work And Good Ideas&#8217;</a></li>
</ul>
Photo: Shutterstock

Earnings

Long Ideas

Options

Options Corner: A Poor Performance By Micron May Signal An Incoming Rebound

Carbon Revolution Public Limited Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) shares are soaring Tuesday after the company announced $25 million in financing to support the <a href="https://www.benzinga.com/pressreleases/24/12/g42663136/carbon-revolution-secures-new-25-million-financing-agreement-with-oic-and-existing-lenders">ongoing liquidity of its business</a>.
What Happened: Carbon Revolution, a global manufacturer of carbon fiber wheels, said it reached an agreement with Orion Infrastructure Capital for a further $25 million in financing to be released in five $5 million tranches. Existing noteholders have also agreed to release up to $2 million of existing loan reserves in five equal tranches.
In connection with the release of each of the five tranches, Carbon Revolution will issue to Orion Infrastructure Capital and the lenders penny warrants to purchase 5% of the company&#8217;s outstanding shares.
Carbon Revolution previously drew $70 million of its $110 million funding agreement with Orion Infrastructure Capital. The new $25 million agreement will be drawn from the remaining $40 million under the agreement.
&#8220;OIC continues to be a great funding partner for Carbon Revolution, sharing our vision for our world-leading technology,&#8221; said Jake Dingle, CEO of Carbon Revolution. &#8220;This capital supports the ongoing liquidity of the business and underpins the continued delivery of our production capacity increase and the near-term launch of a number of new OEM programs.&#8221;
See Also: <a href="https://www.benzinga.com/news/large-cap/24/12/42668623/american-airlines-resolves-nationwide-flight-grounding-on-christmas-eve-shares-rebound-after-brief-selloff">American Airlines Lifts Christmas Eve Grounding, Shares Bounce Back</a>
Carbon Revolution also noted that it continues to work to file its annual report &#8220;as promptly as practical&#8221; in order to regain compliance with Nasdaq listing rules. 
It&#8217;s worth noting that Carbon Revolution is considered a low-float stock with just 1.81 million shares available for public trading, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The company also had a market cap of less than $7.5 million as of Monday's close. Low-float, micro-cap stocks can be extremely volatile, which may help explain some of Tuesday's outsized move.
CREV Price Action: <a href="http://benzinga.com/quote/crev">Carbon Revolution shares</a> were up 158.9% at $10.12 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Financing

CREV

Carbon Revolution Stock Is Soaring Today: What's Going On?

Reinsurance Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) short percent of float has risen 14.81% since its last report. The company recently reported that it has 315 thousand shares sold short, which is 0.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Reinsurance Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735055121_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Reinsurance Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Reinsurance Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Reinsurance Gr's peer group average for short interest as a percentage of float is 1.61%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Reinsurance Gr?

Yum Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) short percent of float has risen 13.7% since its last report. The company recently reported that it has 6.95 million shares sold short, which is 2.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Yum Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735055115_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Yum Brands has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Yum Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Yum Brands's peer group average for short interest as a percentage of float is 9.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Yum Brands's Recent Short Interest

AptarGroup's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>) short percent of float has fallen 17.24% since its last report. The company recently reported that it has 422 thousand shares sold short, which is 0.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AptarGroup Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735055110_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AptarGroup has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AptarGroup's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AptarGroup's peer group average for short interest as a percentage of float is 3.77%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About AptarGroup?

AptarGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>) has outperformed the market over the past 20 years by 1.04% on an annualized basis producing an average annual return of 9.37%. Currently, AptarGroup has a market capitalization of $10.55 billion. 
Buying $1000 In ATR: If an investor had bought $1000 of ATR stock 20 years ago, it would be worth $5,916.03 today based on a price of $158.52 for ATR at the time of writing.
<h3>AptarGroup's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735055109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In AptarGroup 20 Years Ago Would Be Worth This Much Today

Despite a week of market chaos sparked by the Federal Reserve's hawkish stance, Bank of America clients leaned into risk, driving massive inflows into equities <a href="https://www.benzinga.com/etfs">and exchange traded funds.</a>
Data released Tuesday shows that BofA clients poured nearly $10 billion into U.S. assets — the second-largest inflow on record since 2008 and the biggest since January 2017.
Jill Carey Hall, a Bank of America analyst, highlighted a streak of seven consecutive weeks of inflows and said that, as in the previous five weeks, clients favored both single stocks and ETFs, with larger inflows directed toward single stocks.
The four-week moving average of inflows rose to $6.36 billion, the highest on record.
This appetite for risk came even as the S&amp;P 500, as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), tumbled 2% for the week, with Wednesday volatility spiking to its highest level since 2018.
While Fed Chair Jerome Powell&#8216;s <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42628985/traders-fight-the-grinch-to-save-the-santa-rally-10-sp-500-stocks-poised-for-a-year-end-surge">hawkish rhetoric rattled markets</a>, the flows story underscores a crucial trend: investors remain willing to aggressively buy the dip.
<h3 class="wp-block-heading">Institutional Buying Surges, Hedge Funds Sell</h3>
A closer look at the data revealed divergent behaviors across investor groups. 
Institutional clients, often considered market bellwethers, were net buyers for the third consecutive week, driving the largest rolling four-week inflows in nine months. 
Bank of America analysts highlighted that this trend often follows October's tax-loss selling season for mutual funds. Retail investors also joined the buying spree, marking their second consecutive week of inflows. 
In contrast, hedge funds remained sellers for a second straight week. 
Private clients, traditionally heavy sellers in December due to tax-loss harvesting, were less aggressive this year, with their single-stock selling activity "slightly less so than in the average December," according to Hall.
Notably, while private clients leaned into ETFs, corporations continued their stock buybacks at a pace that is on track to set a record high for the year when measured as a percentage of the S&amp;P 500's market cap. 
<h3 class="wp-block-heading">Tech, Industrials Shine, Health Care Suffers</h3>
Breaking down the flows by sectors, tech stocks emerged as the strongest performers, netting $4.3 billion in inflows. 
Industrial stocks followed with their largest inflows since February 2022, while Consumer Staples also saw robust buying.
Conversely, Health Care and Consumer Discretionary stocks led the outflows, with Health Care seeing net selling in four of the last five weeks. 
ETF flows painted a similar picture, with tech and industrial ETFs dominating inflows while Financials and Real Estate experienced the most significant outflows.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42658817/5-semiconductor-stocks-wall-street-analysts-predict-could-soar-in-2025">5 Semiconductor Stocks Wall Street Analysts Predict Could Soar In 2025</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Analyst Color

Equities

Large Cap

Broad U.S. Equity ETFs

Hedge Funds

Econ #s

Federal Reserve

ETFs

Investors Aggressively Bought Stocks, ETFs In Volatile Fed Week: Bank Of America Reveals Largest Inflows Since 2017

<a href="https://x.com/FuzzyPandaPA/status/1871580678103650585">https://x.com/FuzzyPandaPA/status/1871580678103650585</a>
&nbsp;

UMAC

FuzzyPandaPA Posts On X "Wow, this is a new mgmt strategy. $UMAC essentially just published a short report on themselves. We are inclined to agree with their analysis"

WiMi Hologram Cloud Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIMI#NASDAQ">WIMI</a>) shares traded higher in the <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket session</a> on Tuesday, but gave up the gains in the regular trading session.
The firm has made significant strides in quantum computing by developing its Machine Learning-based <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42647055/wimi-develops-quantum-error-mitigation-technology-based-on-machine-learning" rel="noreferrer noopener">Quantum Error Suppression Technology (MLQES).</a>
WiMi Hologram said in a press release that this technology addresses a major challenge in quantum computing: error correction.
Quantum devices, which rely on qubits, often face issues like noise, thermodynamic disturbances, and external interference, leading to errors in calculations.
Read Next: <a target="_blank" href="https://www.benzinga.com/24/12/42640560/japan-cannot-happen-here-was-common-refrain-20-years-ago-in-the-west-mohammed-el-erian-says-as-tokyo-climbs-out-of-the-hole-this-country-looks-at-risk-of-falling-in" rel="noreferrer noopener">Mohammed El Erian Says This Country Faces Japan-Style Economic Risk Even As Tokyo Rebounds</a>
Traditional error correction methods require additional qubits or complex error-correcting codes, which consume valuable quantum resources and add complexity.
WiMi&#8217;s MLQES, however, offers a solution by leveraging machine learning to predict and suppress errors without needing extra quantum resources, the company said.
The system uses a supervised learning model trained on historical quantum circuits to predict potential errors in real time.
When the error value exceeds a set threshold, MLQES triggers a segmentation mechanism that breaks down large quantum circuits into smaller, manageable sub-circuits. These sub-circuits can operate independently, reducing noise and error propagation.
Once completed, the results from these sub-circuits are sent to a classical computer for further processing, where a classical reconstruction algorithm combines them into the final output.
WiMi said that by reducing the reliance on error-correcting codes and improving computational efficiency, MLQES paves the way for more practical and accessible quantum computing applications, accelerating advancements in fields like artificial intelligence and materials science.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, WIMI stock has gained over 51% in the past year.
Price Action: WIMI shares are trading lower by 5.83% to $1.13 at last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42667439/us-stocks-to-open-higher-on-shortened-trading-day-as-santa-clause-rally-period-begins-says-analyst" target="_blank" rel="noreferrer noopener">US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst</a></li>
</ul>

General

WIMI

What's Going On With WiMi Hologram Cloud Stock On Tuesday?

Price-to-book value is irrelevant, according to conventional wisdom.
The common argument states that all that matters is Central Bank liquidity and the total addressable market. It has been a powerful story with massive tailwinds from technology and politics.
Today, intangible assets, like intellectual property and brand value, matter the most.
Critics claim that only &#8220;dinosaurs&#8221; use price-to-book value, and most of them are extinct.
&nbsp;None of the biggest fund managers or self-proclaimed experts on the internet pay attention to the price of tangible book value.
&#8220;Value investing is dead,&#8221; they say, &#8220;and even if it weren&#8217;t, metrics like EBITDA and adjusted non-GAAP cash flow measures would be much more important than asset value.&#8221;
&nbsp;I write some version of this column every four or five months, as this remains the widely accepted opinion.
That may be true if you&#8217;re managing billions of dollars and need to dump millions of shares instantly to justify your existence.
If you feel compelled to be part of the tribe and own all the same stocks everybody else does, deep-value investing based on tangible book value is probably not for you.
However, if you&#8217;re an individual investor looking to grow your wealth to finance the life that&#8217;s important to you, then deep-value investing isn&#8217;t only alive, it's probably your best choice.
If you want to achieve high returns without sitting in front of screens or losing sleep over market volatility, the deep-value approach may be ideal for you.
The heart of deep-value investing is buying companies that trade for the value of their assets minus all debt and obligations.
Unlike most analysts who rely on earnings forecasts, deep-value analysts approach the matter from a credit-first perspective.
The simple truth is that a credit-first, deep-value approach to investing has outperformed the market over almost any measurable period.
The market has just experienced one of its best decades ever, with index fund investors earning over 13%.
For every dollar the successful index fund investor has earned over the decade, investors who used the combination of credit and value would have earned $4.39.
2024 has been a fantastic year for large-cap stock investors, yet deep-value investors who focused on credit have performed even better.
&nbsp;At no point in this journey would you have owned the stocks everyone loved. Over two decades, you would have owned few tech stocks.
&nbsp;Your holdings would have been old-economy stalwart businesses that everyone ignored.
&nbsp;Many of them would have been acquired by private equity firms and strategic buyers who recognized the value of adding these businesses to their existing operations over the years..
You would own more stocks at market bottoms than at market tops, as bargains become scarce as markets move higher.
Today is no exception.
While you won&#8217;t own any high-tech companies on the cutting edge of artificial intelligence, you will own companies that will be key providers of the energy needed for the economy to grow and support the expansion of AI and other technologies.
Consider PBF Energy Inc. (Ticker: PBF), one of North America&#8217;s largest independent petroleum refiners and suppliers. Headquartered in Parsippany, New Jersey, the company owns and operates a diverse portfolio of refining assets strategically located across the United States. PBF Energy also operates a logistics subsidiary, PBF Logistics LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBFX#NYSE">PBFX</a>), which provides transportation, storage, and terminal services to support its refining operations and third-party customers.
The stock currently trades at less than 60% of its tangible book value and has a strong credit profile. It pays a dividend yield of 3.6%, so investors collect cash while waiting for the price to reflect the company&#8217;s value. The decline in the stock price has attracted significant buying from Mexican billionaire and activist investor Carlos Slim, who owns 23% of the company.
Another example lies in shipping. Everyone claims the shipping business is terrible, arguing that China will never make, sell, or buy anything ever again, and that trade tariffs will bring global trade to a screeching halt. While I have no idea how things will play out for the global economy given China&#8217;s ongoing difficulties or the looming prospect of punitive tariffs, I do know that Genco Shipping (Ticker: GNK) trades for less than the value of its ships and has a strong balance sheet.
The fundamentals of the business are fantastic despite the industry&#8217;s negative perception. Genco Shipping is a leading provider of dry bulk shipping services. Based in New York, the company operates a modern and diversified fleet of dry bulk vessels. As of October 2024, Genco&#8217;s fleet comprises 42 vessels, including various sizes of freight carriers. The fleet has a total carrying capacity of approximately 4.45 million deadweight tons and an average age of 11.9 years.
Genco continues to execute its comprehensive value strategy, focusing on paying substantial quarterly cash dividends, making voluntary debt repayments, and opportunistically growing and renewing its asset base. In line with this strategy, the company acquired the Genco Intrepid, a high-specification 2016-built 180,000 dwt Capesize vessel, delivered in October 2024. The stock yields over 10% at the current price and trades for just 65% of tangible book value and 8 times earnings. Wall Street pays very little attention to these stocks, and internet pundits have no idea these companies even exist. Deep-value investors who understand the power of valuation, credit, and patience could do very well with both of these stocks.

Opinion

PBFX

Under the Radar: The Untapped Potential of Price-to-Book Value Investing

After a solid first-quarter earnings report, Vertex Pharmaceuticals (VRTX) comfortably topped analysts' earnings and revenue estimates in the first quarter. But should investors consider adding the stock to their portfolio now? Let's look at its financial metrics to gauge its prospects… On May 6, 2024, Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), a pharmaceutical company pioneering in the field of Cystic Fibrosis (CF), reported solid first-quarter results as the company saw progress in its R&amp;D pipeline. Its net product revenues increased 13.3% year-over-year to $2.69 billion, while its non-GAAP <a href="https://www.investopedia.com/terms/o/operatingearnings.asp">operating income</a> surged 48.1% from the prior-year quarter to $1.34 billion.
Additionally, its non-GAAP net income came in at $1.24 billion or $4.76 per common share, representing more than a 56% year-over-year increase. However, as of March 31, 2024, VRTX's cash and cash equivalents and marketable securities amounted to $10.17 billion, down from $11.22 billion as of December 31, 2023.
Moreover, the company comprehensively surpassed Wall Street's EPS and revenue estimates. For the first quarter, VRTX's earnings per share was 17.2% above the consensus estimate, and its revenue was 4.3% higher than the analysts' estimates. It is no surprise that VRTX's strong earnings have topped the EPS estimates in each of the past consecutive four quarters.
Shares of VRTX have gained 18.8% over the past nine months and 17.9% over the past year to close the last trading session at $410.24.
Here are the fundamental aspects of VRTX that could influence its price performance in the near term:
Positive Developments
Last month, the company entered into a definitive agreement to acquire Alpine Immune Sciences, Inc. (<a href="https://stocknews.com/stock/ALPN/">ALPN</a>) for approximately $4.9 billion in cash. This deal includes obtaining povetacicept, a Phase 3-ready asset known for its potential in treating IgA nephropathy and its status as a potential pipeline-in-a-product.
VRTX's CEO, Reshma Kewalramani, views the acquisition as strategically advantageous, as it aligns with The company's mission to address unmet needs in specialty markets. Further, this move aims to integrate ALPN's protein engineering and immunotherapy capabilities into the VRTX's portfolio.
On top of this, VRTX reached a clinical milestone for VX-670 in DM1 in the first quarter of 2024, triggering a $75 million milestone payable to Entrada.
Favorable Analyst Estimates
The consensus revenue estimate of $2.66 billion for the fiscal second quarter (ending June 2024) represents a 6.7% increase year-over-year. The consensus EPS estimate of $4.17 for the current quarter indicates a 7.2% improvement year-over-year. The company has an excellent surprise history, surpassing the consensus revenue estimates in three of the trailing four quarters.
VRTX's revenue and EPS for the current year (ending December 2024) are expected to grow 9% and 11.6% year-over-year to $10.75 billion and $17.02, respectively. Looking ahead, analysts forecast an 8.8% and 6.7% year-over-year growth in VRTX's revenue and EPS for fiscal year 2025, projecting figures of $11.70 billion and $18.16, respectively.
Discounted Valuation
In terms of forward non-GAAP PEG, VRTX is currently trading at 0.75x, 60.5% lower than the industry average of 1.89x. Its forward P/E multiple of 26.19 is 4.5% lower than the industry average of 27.53x.
In addition, the stock's trailing-12-month EV/EBIT of 20.50x is 9.6% lower than the 23.18x industry average.
Robust Profitability
VRTX's trailing-12-month EBITDA margin of 44.87% is 728.8% higher than the 5.41% industry average. The stock's trailing-12-month levered FCF margin of 35.57% is significantly higher than the 0.53% industry average.
Further, its trailing-12-month net income margin, ROCE, and ROTA of 39.46%, 24.38%, and 16.81% compares to the negative industry averages of 5.52%, 40.87%, and 29.54%, respectively.
POWR Ratings Exhibit Solid Prospects
VRTX's solid outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories.
VRTX boasts a B grade for Value, mirroring its discounted valuation. Additionally, it also earns a B for Quality, reflecting its superior profitability metrics compared to industry standards.
The stock is ranked #8 out of 359 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/VRTX/">Click here</a> to access VRTX's Growth, Momentum, Stability, and Sentiment ratings.
Bottom Line
VRTX kicked off the year on a strong note, with sharp increases in profits and revenue in the first quarter, primarily fueled by the robust uptake of Trikafta among younger patients. Moreover, the anticipation of regulatory approvals for VRTX's therapies across various global regions signals a promising outlook for the company's expansion and market reach.
Additionally, the company's reaffirmed revenue guidance for fiscal year 2024 (total product revenues are expected to range from $10.55 billion to $10.75 billion) reflects a confident outlook for sustained growth in the cystic fibrosis sector, alongside the potential introduction of Casgevy in new indications and markets.
Plus, the activation of treatment centers for Casgevy and the collection of cells from patients for its commercial launch in sickle cell disease and transfusion-dependent Beta-thalassemia are some promising developments.
Given these factors, coupled with robust profitability, optimistic analyst estimates, and discounted valuation underscore the company's strong financial position and the potential for future earnings growth.
Hence, we believe that investing in this stock could help you garner substantial returns.
How does Vertex Pharmaceuticals Incorporated (VRTX) Stack Up Against its Peers?
Other stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> sector that may be worth considering are Sino Biopharmaceutical Limited (<a href="https://stocknews.com/stock/SBHMY/">SBHMY</a>), Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), and Otsuka Holdings Co., Ltd. (<a href="https://stocknews.com/stock/OTSKY/">OTSKY</a>) - they have an overall rating of A (Strong Buy). <a href="https://stocknews.com/category/biotech/">Click here</a> to explore more Biotech stocks.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
VRTX shares were trading at $423.48 per share on Wednesday afternoon, up $13.24 (+3.23%). Year-to-date, VRTX has gained 4.08%, versus a 9.10% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/vrtx-sbhmy-gild-otsky-alpn-vertex-pharmaceuticals-vrtx-earnings-review-is-it-time-to-buy/>Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?

Sino Biopharmaceutical Limited goes ex dividend tomorrow

Given Organogenesis's (ORGO) upbeat first-quarter results and promising development of its ReNu program for knee osteoarthritis, the company seems to be on the brink of significant growth. Let's delve into its fundamentals to determine whether it's a hidden gem in the biotech sector. Read more to find out… Leading wound care specialist Organogenesis Holdings Inc. (<a href="https://stocknews.com/stock/ORGO/">ORGO</a>) surpassed Wall Street's expectations in the first quarter of fiscal 2024. The company reported revenue of $109.98 million, well above the analysts' estimate of $100.23 million. This figure also outpaced their guidance, which projected revenue between $98 million and $104 million, driven by a surge in momentum from February into March.
Building on the momentum, Organogenesis forecasts positive growth for the year ending December 31, 2024. The company expects net revenue to range between $445 million and $470 million, marking a year-over-year increase of 3% to 9% compared to the $433.1 million reported for 2023. However, the profitability outlook is mixed, with expected adjusted <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> (loss) ranging from ($8.1) million to $7.1 million and adjusted EBITDA between $15.8 million and $35.0 million.
While revenue growth is strong, Organogenesis has been experiencing an unsettling string of earnings contractions, which could pose a challenge in the near term. ORGO's net loss per share was $0.02, compared to the consensus estimate of 0.03.
Shares of ORGO have gained 1.5% over the past month to close the last trading session at $2.70. However, the stock has plunged 21.9% over the past year and 33.7% year-to-date.
Let's look at factors that could influence ORGO's performance in the upcoming months.
Promising Progress in ReNu Phase III Clinical Trials
Organogenesis has made notable progress with its ReNu program, which aims to manage knee osteoarthritis (OA) symptoms. Recently, the company shared<a href="https://investors.organogenesis.com/news-releases/news-release-details/organogenesis-achieves-primary-endpoint-phase-3-clinical-trial"> positive top-line results</a> from its first Phase III clinical trial, achieving the primary endpoint with a p-value of 0.0177. The trial demonstrated a significant reduction in knee OA pain over six months compared to a saline control group.
By 2027, an estimated 34.4 million Americans will be affected by knee OA. ReNu could offer a non-surgical pain management option, particularly for the most severe cases, representing around 5 million people. If approved, ReNu would be the only FDA-approved biologic intra-articular injection for this purpose, marking a significant advancement in the treatment of knee OA.
Mixed Financial Performance
For the first quarter that ended March 31, 2024, ORGO's net revenues increased 2.2% year-over-year to $109.98 million. Revenue from Advanced Wound Care rose 3% from the prior year to $103.9 million, while the net revenue for Surgical and Sports Medicine products was $6.1 million, down 9% year-over-year. Its gross profit grew marginally from the year-ago value to $81.28 million.
ORGO's loss from operations narrowed 3.7% from the previous year's quarter to $3.85 million. The company's net loss came in at $2.10 million compared to $2.97 million last year, while its net loss per share remained flat year-over-year at $0.02. However, ORGO recorded an adjusted EBITDA of $2.55 million in the same quarter.
As of March 31, 2024, Organogenesis' cash and cash equivalents stood at $88.63 million, compared to $103.84 million as of December 31, 2023.
Mixed Analyst Estimates
Analysts expect ORGO's EPS to increase 5.7% year-over-year to $114.73 million for the third quarter ending September 2024. For the fiscal year ending December 2024, its revenue is expected to reach $453.76 million, registering a year-over-year growth of 4.8%.
However, the company is estimated to post a loss per share of $0.01 in the current quarter and remain negative for the fiscal year 2024. Nonetheless, ORGO has an impressive earnings surprise history, surpassing the consensus EPS estimates in three of the trailing four quarters.
Discounted Valuation
In terms of forward EV/Sales, ORGO is trading at 0.88x, which is 74.2% lower than the industry average of 3.42x. Similarly, the stock's forward Price/Sales multiple of 0.82 is 76.9% lower than the industry average of 3.54x. Additionally, the stock's 2.64x forward Price/Book is 1.2% below the industry average of 2.67x.
POWR Ratings Reflect Uncertainty
ORGO's mixed fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of C, which translates to Neutral in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. ORGO has an A grade in Value, which aligns with its lower-than-industry valuation. However, with a five-year beta of 1.66, the stock has earned a grade C for Stability.
Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, ORGO is ranked #47 out of 342 stocks.
Beyond what I have stated above, we have also given ORGO grades for Growth, Momentum, Sentiment, and Quality. Get all ORGO ratings <a href="https://stocknews.com/stock/ORGO/">here</a>.
Bottom Line
Organogenesis is an anomaly among small biotechs, achieving modest revenues despite inconsistent earnings and a promising catalyst in ReNu. However, this inconsistency in earnings has proven to be a significant stumbling block. While optimism about its long-term potential is contingent upon securing FDA approval for ReNu, recent mixed financial performance and an uncertain near-term outlook raise concerns.
Given these uncertainties and the volatility typically associated with biotech investments, waiting for a better entry point in this stock seems wise now.
How Does Organogenesis Holdings Inc. (ORGO) Stack Up Against Its Peers?
Given its near-term uncertain prospects, the odds of ORGO outperforming in the weeks and months ahead are compromised. However, there are many industry peers with much more impressive POWR Ratings. So, consider these three A (Strong Buy) stocks from the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), Nippon Shinyaku Co., Ltd. (<a href="https://stocknews.com/stock/NPPNY/">NPPNY</a>), and Sino Biopharmaceutical Limited (<a href="https://stocknews.com/stock/SBHMY/">SBHMY</a>).
To explore more A and B-rated biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ORGO shares were trading at $2.74 per share on Monday afternoon, down $0.06 (-2.14%). Year-to-date, ORGO has declined -33.01%, versus a 15.51% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/orgo-gild-nppny-sbhmy-is-organogenesis-a-hidden-gem-in-the-biotech-sector/>Is Organogenesis a Hidden Gem in the Biotech Sector?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Organogenesis a Hidden Gem in the Biotech Sector?

Veracyte (VCYT) exceeded Wall Street's expectations in its first-quarter earnings report and is well-positioned to capitalize on the expanding genomic diagnostics market. However, with its stretched valuation and increased volatility, is VCYT a smart investment? Read on to find out… Genetic testing, a critical medical procedure, identifies alterations in genes, chromosomes, or proteins to confirm or rule out genetic conditions and assess an individual's risk of developing or passing on such disorders. This market is booming, with the global genetic testing market projected to grow from $8.84 billion in 2023 to an estimated <a href="https://www.biospace.com/article/releases/genetic-testing-market-size-to-set-usd-64-73-billion-by-2033/">$64.73 billion by 2033</a>, driven by technological advancements, increased awareness, and expanding applications. The U.S. genomics market alone is set to reach around $43.81 billion by 2032, growing at a <a href="https://www.precedenceresearch.com/genomics-market#:~:text=The%20U.S.%20genomics%20market%20size,the%20Middle%20East%2C%20and%20Africa.">CAGR of 19.4%</a>.
Thus, it could be opportune to invest in fundamentally sound biotech stocks. Let's determine whether investors should place their bets on Veracyte, Inc. (<a href="https://stocknews.com/stock/VCYT/">VCYT</a>) in genomic diagnostics.
VCYT is a leading diagnostics company that aims to revolutionize cancer care globally through innovative diagnostics. By leveraging a powerful platform of genomic data, bioinformatics, and AI, Veracyte provides clinicians with vital insights needed for accurate cancer diagnosis and treatment guidance.
The company's first-quarter earnings for 2024 painted a promising picture, with revenue of $96.84 million, exceeding Wall Street expectations of $93.36 million. Its test volume rose by 16% year-over-year to 33,424.
One of Veracyte's significant achievements is the Decipher Prostate Genomic Classifier, which received top-tier recognition in the updated NCCN prostate cancer guidelines. Additionally, VCYT's acquisition of C2i Genomics has broadened its capabilities into minimal residual disease (MRD) testing, marking a significant expansion in its product offerings.
Marc Stapley, Veracyte's CEO, said, "We had a strong start to 2024, driven by robust growth from our market-leading Decipher Prostate and Afirma tests. We executed upon our strategies to further penetrate these markets by expanding our clinical evidence, and, for Decipher, securing enhanced status in guidelines while also achieving a key commercial reimbursement milestone."
Looking ahead, VCYT has raised its full-year 2024 revenue guidance to $402 million to $410 million, representing a year-over-year growth of 11% to 14% and testing growth of 15% to 18%. This optimism is supported by their expectations of ending the year with cash, cash equivalents, and short-term investments ranging from $236 million to $240 million.
Despite these advancements, shares of VCYT have plunged 17.4% over the past six months and 21.9% year-to-date to close the last trading session at $21.47. However, the stock has shown a recent uptick, gaining 4.1% over the past three months.
Let's look at factors that could influence VCYT's performance in the upcoming months.
Mixed Financial Performance
For the first quarter that ended March 31, 2024, VCYT's total revenue increased 17.5% year-over-year to $96.84 million. The company's testing revenue increased by 25% to $90.30 million, up from $72.40 million in the same period last year, primarily driven by the strong performance of the Decipher Prostate and Afirma tests. 
Its non-GAAP income from operations came in at $3.83 million, compared to the prior-year quarter's loss of $1.75 million. The quarter's <a href="https://www.investopedia.com/terms/n/netloss.asp">net loss</a> narrowed 76.9% and 81.8% year-over-year to $1.86 million and $0.02 per share, respectively.
However, VCVY's net cash used in operating activities for the quarter increased to $8.97 million from the year-ago value of $2.17 million. Additionally, as of March 31, 2024, VCYT's cash and cash equivalents stood at $209.19 million, compared to $216.45 million as of December 31, 2023.
Mixed Analyst Expectations
Analysts expect VCYT's revenue for the second quarter (ended June 2024) to grow 10.7% year-over-year to $99.99 million. However, the company is expected to post a loss per share of $0.01 in the same quarter.
Similarly, for the ongoing quarter (ending September 2024), VCYT's revenue is expected to increase 12% year-over-year to $100.95 million. On the contrary, its loss per share for the quarter is estimated to be $0.03.
Nonetheless, for the fiscal year ending December 2024, Street expects VCYT's revenue to grow 12.3% from the prior year to $405.60 million, while its EPS is expected to be $0.01.
Stretched Valuation
In terms of forward non-GAAP P/E, VCYT is trading at 1717.60x, significantly higher than the industry average of 18.81x. The stock's forward EV/Sales and Price/Sales multiples of 3.57 and 4.05 are 8.2% and 14.3% above the respective industry averages of 3.30 and 3.54.
Likewise, its forward EV/EBITDA of 50.88x is 297.6% higher than the industry average of 12.80x. Moreover, the stock's forward Price/Cash Flow ratio of 93.35x compares to the industry average of 14.94x.
Mixed Profitability
VCYT's trailing-12-month gross profit margin of 67.69% is 17.7% higher than the 57.48% industry average. Also, the stock's trailing-12-month levered FCF margin of 9.75% is considerably higher than the industry average of 1.26%.
However, its trailing-12-month asset turnover ratio of 0.32x is 21.6% lower than the industry average of 0.41x. Likewise, the stock's trailing-12-month EBITDA margin of 5.25% is 9.6% lower than the industry average of 5.81%.
POWR Ratings Reflect Uncertainty
VCYT's mixed fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of C, which translates to Neutral in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. VCYT has a C grade for Sentiment, which is consistent with mixed analyst estimates.
The stock also has a C grade for Quality, justified by its mixed profitability. Moreover, with a five-year beta of 1.64, the stock has earned a grade C for Stability.
Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, VCYT is ranked #60 out of 336 stocks.
Beyond what I have stated above, we have also given VCYT grades for Value, Momentum, and Quality. Get all VCYT ratings <a href="https://stocknews.com/stock/VCYT/">here</a>.
Bottom Line
VCYT exceeded analysts' revenue and earnings estimates in the first quarter of 2024, buoyed by strategic market expansion and robust clinical advancements. Despite significant improvement from the previous year's losses, the company continues to face a negative bottom line.
As Veracyte navigates the dynamic landscape of genomic diagnostics, it's crucial to assess whether its innovative approach and strong market position make it a smart bet for investors looking to capitalize on the growth of genetic testing.
Given VCT's elevated valuation and uncertain near-term outlook, waiting for a better entry point in this stock seems wise now.
How Does Corsair Gaming, Inc. (VCYT) Stack Up Against Its Peers?
While VCYT has an overall grade of C, equating to a Neutral rating, you may check out these A (Strong Buy) rated stocks within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), Nippon Shinyaku Co., Ltd. (<a href="https://stocknews.com/stock/NPPNY/">NPPNY</a>), and Sino Biopharmaceutical Limited (<a href="https://stocknews.com/stock/SBHMY/">SBHMY</a>).
To explore more A and B-rated biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>
 

<hr />
VCYT shares were trading at $21.47 per share on Friday afternoon, down $0.00 (0.00%). Year-to-date, VCYT has declined -21.96%, versus a 17.16% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/vcyt-gild-nppny-sbhmy-is-veracyte-a-smart-bet-in-genomic-diagnostics/>Is Veracyte a Smart Bet in Genomic Diagnostics?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Comments

Sino Biopharmaceutical

Notizie

Ultime notizie per Sino Biopharmaceutical (OTC:SBHMY) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO